COL Group has appointed Timothy Oh as chief marketing officer of FlareFlow, adding to his existing role as general manager ...
Efficacy analysis of CDK4/6 inhibitors (CDKi) + endocrine therapy (ET) treatment in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC ...
Construction under way this year on the plant’s 13-million tpy Phase 1 includes foundations, steel and pipe installation, dredging, and major equipment setting. Work was paused 2 weeks ago when a ...
Subcutaneous epcoritamab + R-DHAX/C in patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) eligible for autologous stem cell transplant (ASCT): Preliminary phase 1/2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results